Dr. Roberto Gradnik, CEO
Trained as a physician, Roberto Gradnik has more than 25 years’ experience in the pharmaceutical and biotechnology sector. After holding various positions with the Knoll Group (a subsidiary of the BASF Group), including that of Vice-President International Marketing Cardiovascular, he joined the Serono Group in 1999 as Italy’s General Manager and Head of Southern European Subsidiaries. He was then appointed Executive Vice-President for Europe, in charge of all European markets, and a member of the Executive Committee. He continued in the same position for Merck Serono after the acquisition of Serono by Merck AG. More recently, he was appointed Executive Vice-President, Global Business Unit for Neurodegenerative Diseases for Merck Serono. Since January 1st, 2012 until March 31 st , 2014 he was Chief Executive Officer of Stallergenes, a European biopharmaceutical company specialized in the treatment of severe respiratory allergies with allergen immunotherapy. Roberto Gradnik is President of EBE (European Biopharmaceutical Enterprises).
Nathalie de Valleuil, Office & Communication Manager
Nathalie has an extended experience in advertising and communication project management.
Before joining Ixaltis, she worked in various international agencies in Paris and Geneva, accompanying companies like L’Oréal, Nestlé, Danone, Pfizer, Sanofi-Aventis or P&G in their local and international communication.
Dr. Elisabeth Svanberg, CDO
Elisabeth Svanberg received her MD and PhD from the University of Gothenburg, and is a board certified general surgeon and associate professor of surgery. She joined Serono International based in Geneva Switzerland in 2000. Initially Elisabeth worked in the field of metabolism, particularly wasting conditions, as a natural continuation of her academic and clinical work. Elisabeth subsequently held roles of increasing responsibilities at Serono/Merck Serono before joining Bristol Myers Squibb (BMS) in the United States in 2007. At BMS, Elisabeth served as development leader (2007 and 2011) for dapagliflozin (Forxiga/Farxiga), a first in class medicine now registered and launched worldwide to treat type 2 diabetes, and subsequently was Vice President and Head of the Intercontinental Medical Department responsible for Canada, LatinAmerica, Middle East&Africa, AsiaPacific and Australia/New Zealand (2011- 2014). In 2014 Elisabeth joined Janssen Pharmaceuticals (a Johnson & Johnson Company) as Vice President, Head of the Established Products group managing a portfolio of 90 products, used by an estimated 150 million patients globally.